ReviewInternational journal of molecular sciences2025

Topical Ruxolitinib and Delgocitinib Versus Systemic JAK Inhibitors: A Comparative Safety Review.

Simone Lisa Böll et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.